Zepbound is FDA-approved for specified adult weight-management uses and moderate-to-severe obstructive sleep apnea in adults with obesity. Product-label restrictions apply.
FDA approval has not been verified. An FDA warning letter dated 24 August 2026 identifies marketed survodutide products as unapproved. October Phase 3 publication is not approval evidence.
Wegovy: subcutaneous injection or oral tablet, depending on the approved formulation
FDA status
Wegovy formulations are FDA-approved for specified uses. Higher-dose Wegovy HD was approved on 19 March 2026. Approval is formulation- and indication-specific; this record does not extend every use to all semaglutide brands.
FDA states retatrutide is not a component of an FDA-approved drug; current sponsor sources call it investigational. Trial publication does not establish routine marketing approval.
FDA approved Foundayo on 1 April 2026 for specified adult weight-management use alongside a reduced-calorie diet and increased activity. Current label restrictions apply.
Amylin analogue cagrilintide combined with GLP-1 receptor agonist semaglutide
Administration
Subcutaneous injection in clinical trials
FDA status
Sponsor announced an FDA application on 18 December 2025 and still described CagriSema as investigational on 30 September 2026. Subsequent FDA approval has not been verified.